Press Releases (2005)

LPGA TOUR Star Angela Jerman Educates Americans About Sun Exposure And Skin Health

Tee Off Against AKs Campaign makes first stop on the LPGA TOUR at the Michelob Ultra Open

WILLIAMSBURG, VA — May 4, 2005 — Third year LPGA TOUR golf professional Angela Jerman is teaming up with Dermik Laboratories to host the first stop on the LPGA TOUR for the Tee Off Against AKs Campaign at the 2005 Michelob Ultra Open. Tee Off Against AKs is a public awareness campaign designed to educate the golf community about actinic keratoses (AKs) — pre-cancerous skin lesions — and the need for proper skin protection. During the Michelob Ultra Open, which takes place from May 2 – May 8, 2005 at the Kingsmill Resort in Williamsburg, VA, Jerman will be joined by local board-certified dermatologists, who will provide event participants and spectators with free skin cancer screenings. Spectators will also have an opportunity to have their photo taken with a special UV-camera that will show the extent of existing sun damage on their face at the Tee Off Against AKs sponsorship tent. Patrons can also pick up a free Tee Off Against AKs silicone bracelet at the tent to show their support for this campaign aimed at raising awareness about this precancerous condition.

"Our profession puts us at a higher risk of sun-related conditions due to sun exposure," said Jerman, LPGA TOUR golf professional. "I am hoping we can raise awareness among the millions of American golf enthusiasts about the dangers of sun exposure and the steps they can take to minimize their risk. An additional goal of the program is to encourage the local community to be proactive about their skin health and go to see a dermatologist for a regular check-up."

"Golf enthusiasts are especially at risk for actinic keratosis due to the increased sun exposure they receive on vulnerable body parts, like the face, forearms, and back of the hands," said Dr. Perry Robins, MD, President of The Skin Cancer Foundation. "Prolonged sun exposure is dangerous to the skin; therefore it is important for people to get routinely checked for skin problems."

Jerman will appear at the Tee Off Against AKs sponsorship tent on Thursday, May 5, 2005, from 2-4pm to sign autographs and share her personal experience with chronic sun exposure and what she is doing to reduce her risk of sun related conditions while on tour. In addition, free skin cancer screenings will be offered on the following dates and times: Thursday, May 5, 10 a.m. – 4 p.m.; Friday, May 6, 10 a.m. – 4 p.m.; Saturday, May 7, 10 a.m. – 4 p.m.; Sunday, May 8, 10 a.m. – 4 p.m.

AKs are lesions that typically occur on the face, scalp, arms, or back of hands. AKs begin under the skin's surface, then often emerge as rough or scaly areas that may feel like sandpaper to the touch. They can be tan, pink or the same color as skin. People aged 40 and over who have had chronic sun exposure or a history of repeated sunburns, and burn rather than tan in the sun, and those who spend large amounts of time in the sun without sunscreen are at higher risk for AKs.

About Dermik Laboratories
Dermik Laboratories conducts the North American business of sanofi-aventis Dermatology, the global dermatology unit of sanofi-aventis. Dermik Laboratories has nearly 60 years of experience in the development, marketing and distribution of innovative prescription pharmaceutical products. Dermik has created a new division, Dermik Aesthetics, that will focus on marketing innovative, enduring, and reliable treatments to improve appearance and well-being. Dermik's mission is to foster healthy-looking skin and in turn, a healthy outlook for life.

About sanofi-aventis
The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The sanofi-aventis Group conducts business in the U.S. through its subsidiaries Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc. The sanofi-aventis Group is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. The statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect", "anticipates", "believes", "intends", "estimates" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include those discussed or identified in the public filing with the SEC and the AMF made by sanofi-aventis and Aventis, including those listed under "Forward-Looking Statements" and "Risk Factors" in the sanofi-aventis's annual report on Form 20-F for the year ending December 31, 2003 and those listed under "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in Aventis's annual report on Form F-20 for the year ending December 31, 2003. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.